North Point Portfolio Managers Corp OH Makes New $282,000 Investment in Johnson & Johnson (NYSE:JNJ)

North Point Portfolio Managers Corp OH acquired a new position in shares of Johnson & Johnson (NYSE:JNJ) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 1,702 shares of the company’s stock, valued at approximately $282,000.

Other large investors have also modified their holdings of the company. WealthTrak Capital Management LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $29,000. Conquis Financial LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $33,000. Bernard Wealth Management Corp. purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $36,000. Finally, Runnymede Capital Advisors Inc. purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $38,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $149.81 on Monday. The business’s fifty day simple moving average is $154.07 and its 200-day simple moving average is $153.68. The company has a market cap of $360.44 billion, a PE ratio of 16.66, a PEG ratio of 2.27 and a beta of 0.42. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. Analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, May 27th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.47%. Johnson & Johnson’s dividend payout ratio is presently 57.84%.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Morgan Stanley boosted their price target on Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Wednesday, April 16th. Leerink Partners lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Sanford C. Bernstein reiterated a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Thursday, June 5th. Eleven analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.